The use of Revatio (sildenafil) to treat pulmonary hypertension in patients with valvular heart disease leads to worse clinical outcomes compared to placebo, results from a new clinical trial indicate. Results from the Phase 4 SIOVAC trial (NCT00862043) were presented at a Hot Line Late Breaking Clinical Trials (LBCT)…
News
Actelion’s Uptravi (selexipag) delays the progression of pulmonary arterial hypertension that stems from connective tissue disease, a follow-up analysis of Phase 3 clinical trial findings indicates. People with PAH-CTD also tolerate the therapy fairly well, according to the study. The PAH part of PAH-CTD refers to high blood pressure…
African-Americans with pulmonary hypertension and without health insurance have a two-fold increased risk of dying of this disease compared to white Americans, possibly because of delays in referral and treatment, a retrospective study reports. The study “Health Insurance and Racial Disparities in Pulmonary Hypertension Outcomes,” published in…
Arena Pharmaceuticals will present new information in Barcelona this weekend on its pulmonary hypertension therapy ralinepag, which a clinical trial showed improved patients’ heart blood vessel resistance and exercise capacity. The two presentations at the European Society of Cardiology Congress, Aug. 26-30, will focus on the results of preclinical-trial studies in rats and…
Ventripoint Diagnostics‘ VMS Heart Analysis System, which produces a two-dimensional (2D) volumetric reconstruction model of the heart, accurately measures small changes in the heart’s right ventricle volume and can be used in patients with pulmonary hypertension (PH), a new study finds. The study, “Two-dimensional knowledge-based volumetric reconstruction of the…
Estrogen inhibitors may treat pulmonary vascular disease by correcting metabolic defects in women with pulmonary arterial hypertension (PAH), say researchers at Nashville’s Vanderbilt University. Their study,“Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects,” appeared in the European Respiratory Journal. Most people with hereditary PAH have mutations…
Adcirca (tadalafil) exerts a variety of positive effects that may explain why the therapy improves idiopathic pulmonary arterial hypertension (IPAH), according to an in vitro study. The study, “Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro,” was published…
A treatment given people with chronic myelogenous leukemia (CML) — Sprycel (dasatinib) — is known to cause pulmonary arterial hypertension (PAH) in some. Now, researchers in France report that PAH may persist in 37 percent of these leukemia patients for years after the therapy is stopped, although discontinuation is of…
Reviva Pharmaceuticals‘ RP5063 prevented rats from developing pulmonary arterial hypertension (PAH), according to a Canadian study. In addition to precluding heart and blood vessel damage in the animals, RP5063 decreased levels of cytokines, or proteins associated with inflammation. The study, published in the European Journal of Pharmacology, was titled “…
Bellerophon Therapeutics has updated clinical trials testing its investigative INOpulse system for several forms of pulmonary hypertension (PH). The update is part of the company’s second-quarter 2017 financial report. The INOvation-1 trial (NCT02725372) seeks to evaluate the safety, tolerability and effectiveness of pulsed, inhaled nitric oxide (iNO) compared to placebo…
Tracking long-term changes in measurements associated with pulmonary hypertension patients’ death from heart disease can help doctors do a better job of identifying those at higher risk of such deaths, a study reports. The hallmark of what doctors call pulmonary arterial hypertension due to congenital heart disease, or PAH-CHD, is…
Human cardiotrophin 1 protein (hCT1) stimulates heart muscle growth in rats with induced right heart failure (RHF) due to severe pulmonary arterial hypertension, leading to improved heart function, a new study shows. The results suggest that hCT1 could be beneficial for patients with an intractable form of heart failure. The study, “Cardiotrophin 1…
